ciclopirox has been researched along with Foot Dermatoses in 37 studies
Foot Dermatoses: Skin diseases of the foot, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy and safety of ciclopirox nail lacquer solution 8% used to treat onychomycosis of the toe in the United States and in centers worldwide." | 8.80 | Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. ( Baran, R; Fleckman, P; Gupta, AK, 2000) |
| "Ciclopirox nail lacquer solution 8% is a recent addition to the armamentarium of therapies available to the physician and patient for the treatment of onychomycosis." | 8.80 | Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. ( Gupta, AK, 2000) |
| "We report a case of proximal fold cellulitis in both big toes, associated with a bilateral proximal onychomycosis and an intertrigo of the fourth space due to Fusarium solani." | 7.73 | [Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani]. ( Sellart-Altisent, M; Torres-Rodríguez, JM, 2006) |
| "Our data suggest that a ciclopirox lacquer may be helpful in the treatment of common warts." | 7.71 | [Treatment of therapy refractory verrucae vulgares with a ciclopirox-containing lacquer]. ( Landthaler, M; Reisberger, EM; Szeimies, RM; Wimmershoff, MB, 2001) |
| "Ciclopirox is a synthetic hydroxypyridone antifungal agent." | 6.41 | Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. ( Bohn, M; Kraemer, KT, 2000) |
| "A new water-soluble formulation for a ciclopirox nail lacquer showed similar efficacy to the reference product to eradicate toenail onychomycosis and superiority in the mycological cure defined by negative culture, thus preventing reinfections and recurrences." | 5.69 | Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial. ( Bermejo, R; Briones, VG; Campos, FF; Corrales, A; Igea, SA; Martínez, H; Nieto, C; Otero-Espinar, FJ; Picas, J; Zalacain-Vicuña, AJ, 2023) |
| "Onychomycosis is a relatively common disease accounting for up to 50% of all nail disorders." | 5.36 | Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study. ( Amichai, B; Grunwald, MH; Nathansohn, N; Shemer, A; Trau, H, 2010) |
| "A treatment of onychomycosis comprising chemical avulsion of the pathological nail, ciclopirox cream and nail lacquer is significantly more effective than amorolfine nail lacquer." | 5.17 | A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in ( Ben Osman, A; Bienvenu, AL; Bulai-Livideanu, C; Cazeau, C; Coubetergues, H; Coustou, D; Doss, N; Fazaa, B; Lahfa, M; Mokthar, I; Nouira, R; Paul, C; Picot, S; Turki, H; Voisard, JJ; Zourabichvili, O, 2013) |
| "Based on the patient-level analysis, we concluded that terbinafine is the most cost-effective therapy in the treatment of onychomycosis from a managed care perspective." | 4.82 | Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. ( Amaya, K; Arikian, S; Casciano, J; Doyle, J; Haspel, M; Kahler, K; Shear, N, 2003) |
| "We evaluated the efficacy and safety of ciclopirox nail lacquer solution 8% used to treat onychomycosis of the toe in the United States and in centers worldwide." | 4.80 | Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. ( Baran, R; Fleckman, P; Gupta, AK, 2000) |
| "Ciclopirox nail lacquer solution 8% has been shown to be effective in the treatment of dermatophyte onychomycosis of mild to moderate severity Other studies report the effectiveness of ciclopirox nail lacquer in onychomycosis caused by Candida sp and nondermatophyte molds." | 4.80 | Ciclopirox nail lacquer solution 8% in the 21st century. ( Baran, R; Gupta, AK, 2000) |
| "Ciclopirox nail lacquer solution 8% is a recent addition to the armamentarium of therapies available to the physician and patient for the treatment of onychomycosis." | 4.80 | Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. ( Gupta, AK, 2000) |
| "In 1996, oral terbinafine joined itraconazole and fluconazole on the short list of systemic medications that could be used to treat onychomycosis (although fluconazole was not approved for this indication by the US Food and Drug Administration [FDA], it was commonly used for this purpose)." | 3.83 | Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action. ( Rosen, T; Stein Gold, LF, 2016) |
| " He had been treated with two courses of oral terbinafine and topical 8% ciclopirox for presumed onychomycosis." | 3.81 | Trichophytum rubrum endonyx onychomycosis resistant to standard oral and topical therapies. ( Jellinek, N; Mulvaney, PM; Telang, GH, 2015) |
| "Amorolfine was consistently more cost-effective in terms of weighted average daily treatment cost and cost per patient cured than ciclopirox and tioconazole, when all therapies were used as indicated to treat onychomycosis." | 3.73 | Treatment costs of three nail lacquers used in onychomycosis. ( Adjadj, L; Jäckel, A; Lambert, J; Marty, JP, 2005) |
| "We report a case of proximal fold cellulitis in both big toes, associated with a bilateral proximal onychomycosis and an intertrigo of the fourth space due to Fusarium solani." | 3.73 | [Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani]. ( Sellart-Altisent, M; Torres-Rodríguez, JM, 2006) |
| "Our data suggest that a ciclopirox lacquer may be helpful in the treatment of common warts." | 3.71 | [Treatment of therapy refractory verrucae vulgares with a ciclopirox-containing lacquer]. ( Landthaler, M; Reisberger, EM; Szeimies, RM; Wimmershoff, MB, 2001) |
| "For the four main comparator drugs used to treat toenail onychomycosis in Germany, the clinical response rates (clinical cure plus marked improvement) at the end of the follow-up period (month 12 after starting therapy) were, for itraconazole (1-week pulse dosing): 89." | 3.69 | Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. ( De Doncker, P; Dubois, DJ; Eggleston, A; Gupta, AK; Haneke, E; Tormans, G; Van Doorslaer, EK; Van Rossem, K, 1996) |
| " Study B: More subjects adhered to amorolfine dosage (81." | 2.84 | Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis. ( Sarkany, M; Schaller, M; Sigurgeirsson, B, 2017) |
| "Onychomycosis is a frequent nail disease caused by dermatophytes, yeasts, and nondermatophyte molds." | 2.46 | Onychomycosis. ( Vera-Cabrera, L; Welsh, E; Welsh, O, 2010) |
| "In the treatment of onychomycosis, compliance and drug interactions are important considerations, as diabetic patients frequently take concomitant medications." | 2.45 | Toenail onychomycosis in diabetic patients: issues and management. ( Budihardja, D; Freund, V; Mayser, P, 2009) |
| "Topical treatment of onychomycosis, as opposed to oral therapies, offers a distinct advantage by allowing the patient to apply medication directly to the affected area, thus decreasing the potential for serious adverse events, such as drug toxicity and drug interactions." | 2.42 | Management of onychomycosis with topicals. ( Albert, SF; Weis, ZH, 2004) |
| "Ciclopirox is a synthetic hydroxypyridone antifungal agent." | 2.41 | Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. ( Bohn, M; Kraemer, KT, 2000) |
| "rubrum." | 2.40 | Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. ( Lucky, AW; Ploysangam, T, 1997) |
| "Onychomycosis is a fungal infection mostly induced by dermatophytes such as Trichophyton rubrum." | 1.40 | Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model. ( Müller-Goymann, CC; Täuber, A, 2014) |
| "Onychomycosis is a relatively common disease accounting for up to 50% of all nail disorders." | 1.36 | Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study. ( Amichai, B; Grunwald, MH; Nathansohn, N; Shemer, A; Trau, H, 2010) |
| "Treatment with terbinafine plus ciclopiroxolamine was effective." | 1.35 | Nail infection by Aspergillus ochraceopetaliformis. ( Brasch, J; Egberts, F; Jensen, JM; Tintelnot, K; Varga, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (16.22) | 18.2507 |
| 2000's | 15 (40.54) | 29.6817 |
| 2010's | 15 (40.54) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Zalacain-Vicuña, AJ | 1 |
| Nieto, C | 1 |
| Picas, J | 1 |
| Martínez, H | 1 |
| Bermejo, R | 1 |
| Corrales, A | 1 |
| Campos, FF | 1 |
| Igea, SA | 1 |
| Otero-Espinar, FJ | 1 |
| Briones, VG | 1 |
| Schaller, M | 2 |
| Sigurgeirsson, B | 1 |
| Sarkany, M | 1 |
| Fabrizi, V | 1 |
| Zacconi, I | 1 |
| Principato, M | 1 |
| Pesca, C | 1 |
| Cruciani, D | 1 |
| Crotti, S | 1 |
| Papini, M | 1 |
| Cutrín Gómez, E | 1 |
| Anguiano Igea, S | 1 |
| Delgado-Charro, MB | 1 |
| Gómez Amoza, JL | 1 |
| Otero Espinar, FJ | 1 |
| Paul, C | 1 |
| Coustou, D | 1 |
| Lahfa, M | 1 |
| Bulai-Livideanu, C | 1 |
| Doss, N | 1 |
| Mokthar, I | 1 |
| Turki, H | 1 |
| Nouira, R | 1 |
| Fazaa, B | 1 |
| Ben Osman, A | 1 |
| Zourabichvili, O | 1 |
| Cazeau, C | 1 |
| Coubetergues, H | 1 |
| Picot, S | 1 |
| Bienvenu, AL | 1 |
| Voisard, JJ | 1 |
| Täuber, A | 1 |
| Müller-Goymann, CC | 1 |
| Lipner, S | 1 |
| Scher, RK | 2 |
| Braunsdorf, C | 1 |
| Mailänder-Sanchez, D | 1 |
| Jäckel, A | 2 |
| Müller, J | 1 |
| Borelli, C | 1 |
| Mulvaney, PM | 1 |
| Telang, GH | 1 |
| Jellinek, N | 1 |
| Rosen, T | 3 |
| Stein Gold, LF | 3 |
| Brasch, J | 1 |
| Varga, J | 1 |
| Jensen, JM | 1 |
| Egberts, F | 1 |
| Tintelnot, K | 1 |
| de Berker, D | 1 |
| Mayser, P | 1 |
| Freund, V | 1 |
| Budihardja, D | 1 |
| Shemer, A | 1 |
| Nathansohn, N | 1 |
| Trau, H | 1 |
| Amichai, B | 1 |
| Grunwald, MH | 1 |
| Welsh, O | 1 |
| Vera-Cabrera, L | 1 |
| Welsh, E | 1 |
| Macura, AB | 1 |
| Krzyściak, P | 1 |
| Skóra, M | 1 |
| Gniadek, A | 1 |
| Gupta, AK | 6 |
| Cooper, EA | 1 |
| Casciano, J | 1 |
| Amaya, K | 1 |
| Doyle, J | 1 |
| Arikian, S | 1 |
| Shear, N | 1 |
| Haspel, M | 1 |
| Kahler, K | 1 |
| Werschler, WP | 1 |
| Bondar, G | 1 |
| Armstrong, D | 1 |
| Albert, SF | 1 |
| Weis, ZH | 1 |
| Marty, JP | 1 |
| Lambert, J | 1 |
| Adjadj, L | 1 |
| Torres-Rodríguez, JM | 1 |
| Sellart-Altisent, M | 1 |
| Cohen, PR | 1 |
| Jager, SU | 1 |
| Pönninghaus, JM | 1 |
| Koch, P | 1 |
| Van Doorslaer, EK | 1 |
| Tormans, G | 1 |
| Van Rossem, K | 1 |
| Eggleston, A | 1 |
| Dubois, DJ | 1 |
| De Doncker, P | 1 |
| Haneke, E | 1 |
| Ploysangam, T | 1 |
| Lucky, AW | 1 |
| Bohn, M | 1 |
| Kraemer, KT | 1 |
| Fleckman, P | 1 |
| Baran, R | 3 |
| Szeimies, RM | 1 |
| Wimmershoff, MB | 1 |
| Reisberger, EM | 1 |
| Landthaler, M | 1 |
| Galitz, J | 1 |
| Yu, B | 1 |
| Zhou, G | 1 |
| Wang, B | 2 |
| Ben, Y | 1 |
| Yan, H | 1 |
| Shao, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study[NCT03814343] | Phase 4 | 19 participants (Actual) | Interventional | 2019-01-15 | Completed | ||
| A Placebo Controlled, Randomized, Prospective Study to Evaluate the Efficacy and Safety of PinPointe FootLaser in Patients Who Have Failed Oral Terbinafine Treatment for Onychomycosis[NCT01920178] | 7 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to Financial support of the Study withdrawn by Nuvolase, Inc ( PinPointe FootLaser) due to delayed start of the Study and inadequate subjects enrolled) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01920178)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| PinPointe Foot Laser | 0 |
| Sham Laser Group | 0 |
13 reviews available for ciclopirox and Foot Dermatoses
| Article | Year |
|---|---|
Clinical practice. Fungal nail disease.
Topics: Administration, Oral; Administration, Topical; Aged; Antifungal Agents; Ciclopirox; Debridement; Dia | 2009 |
Toenail onychomycosis in diabetic patients: issues and management.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Ciclopirox; Comorbidity; Diabetes | 2009 |
Onychomycosis.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Administration | 2010 |
Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Topics: Adult; Antifungal Agents; Ciclopirox; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; | 2003 |
Assessing treatment outcomes in toenail onychomycosis clinical trials.
Topics: Antifungal Agents; Ciclopirox; Clinical Trials as Topic; Foot Dermatoses; Humans; Itraconazole; Naph | 2004 |
Management of onychomycosis with topicals.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Foot Dermatoses; Humans; Onychomycosis; Pyri | 2004 |
Topical and surgical treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Combined Modality Therapy; Debridement; Foot | 1994 |
Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature.
Topics: Allylamine; Antifungal Agents; Child; Child, Preschool; Ciclopirox; Coloring Agents; Female; Foot De | 1997 |
Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Topics: Administration, Topical; Animals; Antifungal Agents; Cattle; Ciclopirox; Clinical Trials as Topic; D | 2000 |
Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Topics: Administration, Topical; Adult; Aged; Analysis of Variance; Antifungal Agents; Ciclopirox; Clinical | 2000 |
Ciclopirox nail lacquer solution 8% in the 21st century.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Foot Dermatoses; Forecasting; Humans; Onycho | 2000 |
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Arthrodermataceae; Ciclopirox; Cos | 2000 |
Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
Topics: Administration, Topical; Antifungal Agents; Ciclopirox; Drug Costs; Foot Dermatoses; Griseofulvin; H | 2002 |
4 trials available for ciclopirox and Foot Dermatoses
20 other studies available for ciclopirox and Foot Dermatoses
| Article | Year |
|---|---|
Toenail onychomycosis by Trichophyton rubrum and concurrent infestation with Tyrophagus putrescentiae.
Topics: Aged; Agricultural Workers' Diseases; Animal Husbandry; Antifungal Agents; Ciclopirox; Diabetes Mell | 2017 |
Microstructural alterations in the onychomycotic and psoriatic nail: Relevance in drug delivery.
Topics: Administration, Topical; Adult; Antifungal Agents; Ciclopirox; Clobetasol; Foot Dermatoses; Healthy | 2018 |
Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model.
Topics: Animals; Antifungal Agents; Arthrodermataceae; Cattle; Chemistry, Pharmaceutical; Ciclopirox; Foot D | 2014 |
Onychomycosis: current and future therapies.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Debridement | 2014 |
Comparison of user-friendliness and treatment cost of Loceryl® vs. Ciclopoli®--a patient's perspective.
Topics: Administration, Topical; Adult; Antifungal Agents; Ciclopirox; Foot Dermatoses; Germany; Health Care | 2015 |
Trichophytum rubrum endonyx onychomycosis resistant to standard oral and topical therapies.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Resistance, Mul | 2015 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo | 2016 |
Introduction.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocycl | 2016 |
Using Topical Antifungal Medications: Instructions for patients.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocycl | 2016 |
Nail infection by Aspergillus ochraceopetaliformis.
Topics: Antifungal Agents; Aspergillus; Ciclopirox; Female; Foot Dermatoses; Humans; Middle Aged; Naphthalen | 2009 |
Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
Topics: Administration, Topical; Adult; Antifungal Agents; Ciclopirox; Female; Foot Dermatoses; Humans; Lacq | 2010 |
Case report: onychomycosis due to Trichophyton schoenleinii.
Topics: Antifungal Agents; Ciclopirox; Foot Dermatoses; Humans; Male; Middle Aged; Mycological Typing Techni | 2012 |
Treatment costs of three nail lacquers used in onychomycosis.
Topics: Adult; Antifungal Agents; Ciclopirox; Drug Costs; Europe; Female; Foot Dermatoses; Hand Dermatoses; | 2005 |
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
Topics: Antifungal Agents; Cellulitis; Ciclopirox; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug R | 2006 |
Allergic contact dermatitis from cyclopiroxolamine?
Topics: Adult; Antifungal Agents; Ciclopirox; Dermatitis, Allergic Contact; Dermatomycoses; Foot Dermatoses; | 1995 |
Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
Topics: Algorithms; Antifungal Agents; Ciclopirox; Cost-Benefit Analysis; Costs and Cost Analysis; Decision | 1996 |
[Treatment of therapy refractory verrucae vulgares with a ciclopirox-containing lacquer].
Topics: Administration, Topical; Adolescent; Adult; Antifungal Agents; Child; Ciclopirox; Drug Administratio | 2001 |
Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report.
Topics: Administration, Topical; Aged; Antifungal Agents; Ciclopirox; Foot Dermatoses; Humans; Male; Onychom | 2001 |
[New treatments of onychomycoses].
Topics: Administration, Topical; Antifungal Agents; Candidiasis; Ciclopirox; Fluconazole; Foot Dermatoses; H | 1992 |
A clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis.
Topics: Adult; Aged; Antifungal Agents; Candida albicans; Ciclopirox; Female; Foot Dermatoses; Hand Dermatos | 1991 |